Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 24;12(5):e059994.
doi: 10.1136/bmjopen-2021-059994.

Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis

Affiliations

Demographic and clinical characteristics associated with variations in antibody response to BNT162b2 COVID-19 vaccination among healthcare workers at an academic medical centre: a longitudinal cohort analysis

Joseph E Ebinger et al. BMJ Open. .

Abstract

Objectives: We sought to understand the demographic and clinical factors associated with variations in longitudinal antibody response following completion of two-dose regiment of BNT162b2 vaccination.

Design: This study is a 10-month longitudinal cohort study of healthcare workers and serially measured anti-spike protein IgG (IgG-S) antibody levels using mixed linear models to examine their associations with participant characteristics.

Setting: A large, multisite academic medical centre in Southern California, USA.

Participants: A total of 843 healthcare workers met inclusion criteria including completion of an initial two-dose course of BNT162b2 vaccination, complete clinical history and at least two blood samples for analysis. Patients had an average age of 45±13 years, were 70% female and 7% with prior SARS-CoV-2 infection.

Results: Vaccine-induced IgG-S levels remained in the positive range for 99.6% of individuals up to 10 months after initial two-dose vaccination. Prior SARS-CoV-2 infection was the primary correlate of sustained higher postvaccination IgG-S levels (partial R2=0.133), with a 1.74±0.11 SD higher IgG-S response (p<0.001). Female sex (beta 0.27±0.06, p<0.001), younger age (0.01±0.00, p<0.001) and absence of hypertension (0.17±0.08, p=0.003) were also associated with persistently higher IgG-S responses. Notably, prior SARS-CoV-2 infection augmented the associations of sex (-0.42 for male sex, p=0.08) and modified the associations of hypertension (1.17, p=0.001), such that infection-naïve individuals with hypertension had persistently lower IgG-S levels whereas prior infected individuals with hypertension exhibited higher IgG-S levels that remained augmented over time.

Conclusions: While the IgG-S antibody response remains in the positive range for up to 10 months following initial mRNA vaccination in most adults, determinants of sustained higher antibody levels include prior SARS-CoV-2 infection, female sex, younger age and absence of hypertension. Certain determinants of the longitudinal antibody response appear significantly modified by prior infection status. These findings offer insights regarding factors that may influence the 'hybrid' immunity conferred by natural infection combined with vaccination.

Keywords: COVID-19; hypertension; infectious diseases.

PubMed Disclaimer

Conflict of interest statement

Competing interests: JCP, ECF and JLS work for Abbott Diagnostics, a company that performed the serological assays on the biospecimens that were collected for this study.

Figures

Figure 1
Figure 1
Cohort development flow diagram.
Figure 2
Figure 2
Longitudinal trajectory of IgG-S antibody levels following completed BNT162b2 vaccination. Multivariable-adjusted longitudinal trajectories are shown for individuals with a history of prior COVID-19 infection (orange line) and for those without prior COVID-19 infection (green line). Longitudinal estimates with 95% confidence limits (shaded areas) are adjusted for age, sex and hypertension.
Figure 3
Figure 3
Longitudinal trajectory of IgG-S antibody levels following completed BNT162b2 vaccination by prior infection status and age. Multivariable-adjusted longitudinal trajectories are shown for individuals with a history of prior COVID-19 infection and for those without prior COVID-19 infection, including an interaction for age (above vs below median cohort age). Longitudinal estimates with 95% confidence limits (shaded areas) are adjusted for sex and hypertension.
Figure 4
Figure 4
Longitudinal trajectory of IgG-S antibody levels following completed BNT162b2 vaccination by prior infection status and sex. Multivariable-adjusted longitudinal trajectories are shown for individuals with a history of prior COVID-19 infection and for those without prior COVID-19 infection, including an interaction for sex. Longitudinal estimates with 95% confidence limits (shaded areas) are adjusted for age and hypertension.
Figure 5
Figure 5
Longitudinal trajectory of IgG-S antibody levels following completed BNT162b2 vaccination by prior infection and hypertension status. Multivariable-adjusted longitudinal trajectories are shown for individuals with a history of prior COVID-19 infection and for those without prior COVID-19 infection, including an interaction for sex. Longitudinal estimates with 95% confidence limits (shaded areas) are adjusted for age and sex.

References

    1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27:1205–11. 10.1038/s41591-021-01377-8 - DOI - PubMed
    1. Edara VV, Norwood C, Floyd K, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe 2021;29:516–21. 10.1016/j.chom.2021.03.009 - DOI - PMC - PubMed
    1. Corbett KS, Nason MC, Flach B, et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 2021;373:eabj0299. 10.1126/science.abj0299 - DOI - PMC - PubMed
    1. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021;385:1474–84. 10.1056/NEJMoa2109072 - DOI - PMC - PubMed
    1. Zhong D, Xiao S, Debes AK, et al. Durability of antibody levels after vaccination with mRNA SARS-CoV-2 vaccine in individuals with or without prior infection. JAMA 2021;326:2524. 10.1001/jama.2021.19996 - DOI - PMC - PubMed

Publication types